BILLERICA, Mass. (December 9, 2013) – Pharmalucence, Inc. (www.pharmalucence.com) today announced that it has entered into an agreement with Lantheus Medical Imaging, Inc. (www.lantheus.com) to serve as a contract manufacturer of DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography. The contract secures manufacturing capacity for Lantheus at the newly constructed Pharmalucence drug production facility in Billerica, MA for a minimum of 10 years.
Ed Connolly, Pharmalucence Chief Operating Officer, stated, “Pharmalucence has established a world-class manufacturing facility here in New England, which has been recognized by companies who choose to outsource their manufacturing. We are extremely pleased to partner with Lantheus, a local company with a reputation for exceptional product innovation and quality, for the supply of DEFINITY®.”
“Our manufacturing agreement with Pharmalucence is a vital component of our plan to secure long-term supply of DEFINITY®,” said Jeff Bailey, Lantheus President and Chief Executive Officer. “We look forward to working with Pharmalucence, who has a shared commitment to deliver the highest quality products to the customers and patients who benefit from DEFINITY®.”
About Pharmalucence, Inc.
Pharmalucence, www.pharmalucence.com, is a leading provider of Technetium Tc 99m radiopharmaceuticals and contract manufacturer specializing in fill and finish of liquid and lyophilized human injectables. Its new 70,000 sq. ft. manufacturing facility features fully automated, isolated aseptic filling technology for markets worldwide. Founded in 2007, Pharmalucence is a privately-held, U.S. based, employee-owned company.